Evidence Hub

S5.1b Antifungal r esistance

Danila Seidel

Medical Mycology, 2022

Abstract

Abstract S5.1 Antifungal resistance, September 22, 2022, 3:00 PM - 4:30 PM Resistance to clinical antimycotics in Aspergillus fumigatus has become an increasing threat in healthcare worldwide over the past two decades. Factors that contribute to this continuing trend are manifold, among others resistance emerge in environmental fungi through selection pressure due to fungicides widely used in agriculture and farming, resistant clones are diffused around the world through global travel and shipping routes, as well as prophylactic and long-term administration of antifungal agents in patients with chronic fungal disease creating selection pressure. Physicians face particular challenges in their patients with invasive aspergillosis, with emerging resistance adding another layer of therapeutic complexity. We are beginning to gain an understanding of the clinical implications of the different patterns of resistance. First international studies have shown that resistance of A. fumigatus to clinical antifungal agents significantly hampers the successful treatment of patients. This presentation aims to highlight the difficulties associated with antifungal resistance in A. fumigatus with a focus on hematological oncological patients.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free